Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancerThe best of ASCO 2019

被引：0
作者：
Christoph Suppan
Marija Balic
机构：
[1] Medical University Graz,Division of Oncology, Department of Internal Medicine
[2] Medical University Graz,Comprehensive Cancer Center Graz, Subcenter Breast
来源：
memo - Magazine of European Medical Oncology | 2019年 / 12卷
关键词：
Breast cancer; Her2-positive; Adjuvant treatment; Trastuzumab; T‑DM1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.
引用
收藏
页码：312 / 314
页数：2
相关论文
共 49 条
[1]  
Von Minckwitz G(2019)Trastuzumab emtansine for residual invasive Her2-positive breast cancer N Engl J Med 380 617-628
[2]  
Huang CS(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
[3]  
Mano MS(2013)Per-tuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 2278-2284
[4]  
Cortazar P(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-32
[5]  
Zhang L(2018)Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial Lancet Oncol 19 115-126
[6]  
Untch M(2015)Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer N Engl J Med 372 134-141
[7]  
Schneeweiss A(2019)6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial Lancet 393 2599-2612
[8]  
Chia S(2013)6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Lancet Oncol 14 741-748
[9]  
Hickish T(2015)Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with Her2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) Ann Oncol 26 1333-1340
[10]  
Gianni L(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431-1439
12345